Mov­ing up the treat­ment lines, As­traZeneca clinch­es ad­ju­vant breast can­cer OK for Lyn­parza

When As­traZeneca turned up at AS­CO last June to out­line how Lyn­parza cut the risk of can­cer re­cur­rence or death by 42% over place­bo among a group of BR­CA-mu­tat­ed, HER2-neg­a­tive breast can­cer pa­tients, in­ves­ti­ga­tors em­pha­sized how that could set up a first-in-class ap­proval in ear­ly stages of the dis­ease, right af­ter surgery.

That OK is now here, as the FDA green­light­ed the PARP in­hibitor as an ad­ju­vant ther­a­py in this set­ting, the com­pa­ny an­nounced late Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER